Song Hang, Zhao Chan, Zhang Meifen
Peking Union Medical College Hospital, Beijing 100730, China.
Vaccines (Basel). 2022 Oct 8;10(10):1680. doi: 10.3390/vaccines10101680.
This is a retrospective study to investigate the impact of inactivated Coronavirus disease-2019 (COVID-19) vaccination on uveitis flare in patients with uveitis. Sixty patients that were regularly followed up for uveitis for at least two months after the last dose of inactivated COVID-19 vaccines were included in the vaccination group. Sixty patients with comparable characteristics of uveitis who had not received the COVID-19 vaccines were included in the control group. Uveitis flare within 30 days and 60 days after the vaccination in the vaccination group, or after a randomly selected date in the control group, were statistically compared. The flare rate was 16.7% (30 days) and 23.3% (60 days) in the vaccination group, while it was 13.3% (30 days) and 25% (15/60) in the control group. There was no statistical difference in the flare rate of uveitis between the two groups ( = 0.471 for 30 days, = 0.347 for 60 days). Inactivated COVID-19 vaccination appeared not to increase the flare rate in patients with uveitis. Ophthalmologists should give proper and individualized recommendations based on the overall conditions of patients.
这是一项回顾性研究,旨在调查新型冠状病毒肺炎(COVID-19)灭活疫苗接种对葡萄膜炎患者葡萄膜炎发作的影响。接种组纳入了60例在最后一剂COVID-19灭活疫苗接种后至少随访葡萄膜炎两个月的患者。对照组纳入了60例具有相似葡萄膜炎特征但未接种COVID-19疫苗的患者。对接种组接种疫苗后30天和60天内,或对照组随机选择日期后的葡萄膜炎发作情况进行统计学比较。接种组的发作率在30天时为16.7%,60天时为23.3%,而对照组在30天时为13.3%,60天时为25%(15/60)。两组葡萄膜炎的发作率无统计学差异(30天时P = 0.471,60天时P = 0.347)。COVID-19灭活疫苗接种似乎不会增加葡萄膜炎患者的发作率。眼科医生应根据患者的整体情况给出适当的个体化建议。